Compare PTCT & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | HLNE |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.1B |
| IPO Year | 2013 | 2017 |
| Metric | PTCT | HLNE |
|---|---|---|
| Price | $76.81 | $146.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $73.76 | ★ $160.89 |
| AVG Volume (30 Days) | ★ 1.2M | 536.0K |
| Earning Date | 02-26-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | N/A | ★ 19.80 |
| EPS | ★ 8.94 | 5.55 |
| Revenue | ★ $1,779,150,000.00 | $733,070,000.00 |
| Revenue This Year | $127.32 | $8.51 |
| Revenue Next Year | N/A | $20.20 |
| P/E Ratio | ★ $8.64 | $26.15 |
| Revenue Growth | ★ 97.54 | 13.01 |
| 52 Week Low | $35.95 | $111.98 |
| 52 Week High | $87.50 | $179.19 |
| Indicator | PTCT | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 70.59 |
| Support Level | $74.22 | $143.45 |
| Resistance Level | $79.10 | $149.01 |
| Average True Range (ATR) | 2.12 | 3.83 |
| MACD | -0.16 | 0.89 |
| Stochastic Oscillator | 50.16 | 83.26 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.